We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

1 hedge funds and large institutions have $4.08K invested in Array Biopharma Inc in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

96% less capital invested

Capital invested by funds: $110K → $4.08K (-$106K)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BAM
Byrne Asset Management
New Jersey
+$4.08K

Top Sellers

No sellers this quarter

ARRY Hedge Fund Activity: Q3 2025 in Review

1 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2025, worth a combined $4.08K — down 96% from $110K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ARRY positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Byrne Asset Management, opening a new position worth an estimated $4.08K.

  • 1 institutional investor held Array Biopharma Inc (ARRY) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $4.08K of Array Biopharma Inc stock for Q3 2025, down 96% quarter-over-quarter.
  • 1 fund opened new Array Biopharma Inc positions in Q3 2025 and 0 closed out, a net change of +1 holder.
  • The largest Array Biopharma Inc buyer in Q3 2025 was Byrne Asset Management, an estimated $4.08K added.

Based on aggregated 13F filings for Q3 2025.